Protagonist Therapeutics, Inc.

Report azionario NasdaqGM:PTGX

Capitalizzazione di mercato: US$6.4b

Protagonist Therapeutics Gestione

Criteri Gestione verificati 2/4

Protagonist Therapeutics Il CEO è Dinesh Patel, nominato in Dec2008, e ha un mandato di 17.42 anni. la retribuzione annua totale è $ 12.87M, composta da 5.6% di stipendio e 94.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.45% delle azioni della società, per un valore di $ 28.51M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.3 anni e 11.3 anni.

Informazioni chiave

Dinesh Patel

Amministratore delegato

US$12.9m

Compenso totale

Percentuale dello stipendio del CEO5.56%
Mandato del CEO17.4yrs
Proprietà del CEO0.4%
Durata media del management5.3yrs
Durata media del Consiglio di amministrazione11.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • May 15

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • May 08

Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) last week reported its latest first-quarter results, which makes it a...
Seeking Alpha • Jan 30

Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide

Summary Protagonist Therapeutics remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. PTGX’s robust cash position of $678.8 million provides a runway through 2028, supporting aggressive R&D and upcoming commercialization efforts. Both icotrokinra and rusfertide have demonstrated strong efficacy and safety in pivotal trials, with regulatory submissions underway and significant market opportunities ahead. Valuation is premium at 21x EV/sales, reflecting high investor expectations for late-stage pipeline success; downside risk remains if approvals falter. Read the full article on Seeking Alpha
Articolo di analisi • Oct 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shares have been powering on, with a gain...
Articolo di analisi • Jun 13

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders would be excited to see that the share price has had a...
Seeking Alpha • Mar 11

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk. Future PTGX prospects include expanding icotrokinra's use to Crohn's Disease and initiating phase 1 study for PN-881, targeting immune-mediated disorders like hidradenitis suppurativa. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Summary Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032. The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Summary Today, we circle back to the clinical stage of biopharma Protagonist Therapeutics, Inc., whose stock has tripled over the past year. The company has two late-stage drug candidates that are partnered with Takeda and Johnson & Johnson, respectively. If pivotal trials turn out to be successful, both drugs could be approved in 2026. Still more upside in this rally? An updated analysis of Protagonist Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Summary Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for polycythemia vera, faced a clinical hold from the FDA but had the hold removed in October 2021 and now looks approvable. Protagonist's joint plaque psoriasis candidate, JNJ-2113, showed positive results in a Phase 2 study, leading to a stock price increase. Both of Protagonist's lead candidates make a case for a commercial approval - although not for 2 more years at least, and there are risks, and hurdles still to be overcome. 2 Phase 3 studies must still be completed. The recently signed deal with Takeda to co-commercialise Rusfertide is a significant boost for Protagonist and has driven its market cap valuation to $1.64bn - I think that is an accurate reflection for its value for now, but may look to buy on any dips. Read the full article on Seeking Alpha
Seeking Alpha • Jun 08

Protagonist: Too Many Red Flags

Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now.
Seeking Alpha • Feb 01

Protagonist Is Still Being Undervalued Like There's Real Risk

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved. The current valuation is still a deep discount from the highs prior to the dip.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dinesh Patel rispetto agli utili di Protagonist Therapeutics?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$115m

Dec 31 2025US$13mUS$716k

-US$130m

Sep 30 2025n/an/a

US$46m

Jun 30 2025n/an/a

US$52m

Mar 31 2025n/an/a

US$56m

Dec 31 2024US$9mUS$681k

US$275m

Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Compensazione vs Mercato: La retribuzione totale di Dinesh ($USD 12.87M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.38M ).

Compensazione vs guadagni: La retribuzione di Dinesh è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Dinesh Patel (68 yo)

17.4yrs
Mandato
US$12,871,506
Compensazione

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He serves as Additional Non-Execu...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Dinesh Patel
CEO, President17.4yrsUS$12.87m0.45%
$ 28.5m
Asif Ali
Executive VP & CFO4.1yrsUS$3.26m0.0040%
$ 254.5k
Arturo Molina
Chief Medical Officer3.5yrsUS$4.10m0.021%
$ 1.4m
Venkat Thalladi
EVP & Chief Technical Officerless than a yearNessun datoNessun dato
Newman Yeilding
Executive VP1.8yrsNessun datoNessun dato
Matthew Gosling
Executive VP and Chief Legal & Business Officer5.7yrsNessun datoNessun dato
Carena Spivey
Executive VP & Chief Human Resources Officer5.3yrsNessun datoNessun dato
Ashok Bhandari
EVP & Chief Discovery Officer5.3yrsNessun datoNessun dato
Carter King
Executive Vice President of Business Development5.1yrsNessun datoNessun dato
Abha Bommireddi
Executive VP & Chief of Staff5.3yrsNessun datoNessun dato
Samuel Saks
Clinical Development Advisor5.3yrsNessun datoNessun dato
5.3yrs
Durata media
61yo
Età media

Gestione esperta: Il team dirigenziale di PTGX è esperto e expertise (durata media dell'incarico 5.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Dinesh Patel
CEO, President17.4yrsUS$12.87m0.45%
$ 28.5m
Harlan Weisman
Clinical Advisor11.3yrsNessun datoNessun dato
Lewis Williams
Independent Director8.9yrsUS$431.82k0.0080%
$ 509.0k
Chaitan Khosla
Chairman of Scientific Advisory Board11.3yrsUS$188.07kNessun dato
Harold Selick
Independent Chairman17.3yrsUS$428.07k0.090%
$ 5.8m
William Waddill
Independent Director9.8yrsUS$431.82k0.0080%
$ 509.0k
Charles Craik
Scientific Advisorno dataNessun datoNessun dato
Mark Gallop
Scientific Advisorno dataNessun datoNessun dato
Wayne Lencer
Clinical Advisorno dataNessun datoNessun dato
Aida Habtezion
Clinical Advisorno dataNessun datoNessun dato
Ellen Scherl
Clinical Advisorno dataNessun datoNessun dato
Bryan Giraudo
Independent Director8yrsUS$431.82k0.016%
$ 991.9k
11.3yrs
Durata media
68yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PTGX è composto da personale esperto e esperto (durata media dell'incarico 11.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/26 03:25
Prezzo dell'azione a fine giornata2026/05/26 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Protagonist Therapeutics, Inc. è coperta da 19 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research
Timothy ChiangCapital One Securities, Inc.